Statistics Clinical Trials This is an OPML file. It can be used to export all the MedWorm RSS feeds on this topic into your personal RSS reader (usually you have to save this file to your own computer before clicking on an Import OPML command in your own feed reader to upload the file which will then import all the feeds) or it can be used by webmasters to integrate MedWorm feeds with their own website. This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader, such as GoogleReader, or to display this data on your own website or blog. Subscribe to this data using MyMedWorm.Subscribe to this data using GoogleReader.Subscribe to this data using Bloglines.Subscribe to this data using MyYahoo.

This page shows you the most recent publications within this specialty of the MedWorm directory.

The Application of a Wireless Sensor Technology for Vital Statistics in CHILDREN AND ADULTS
Conditions: Fever; COPD; Obesity; Congenital Heart Disease; Respiratory DistressInterventions: Device: Cardiorespiratory monitor; Device: Wireless pressure sensorSponsors: Lawson Health Research Institute; Lawson Health Research InstituteNot yet recruiting - verified April 2013 (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 25, 2013 Category: Research Source Type: clinical trials

Further analysis of the ARISER study identifies a subgroup which shows significant improvement of disease-free survival with RENCAREX
• Patients expressing high CAIX tumour levels in clear cell renal cell carcinoma (ccRCC) show a statistically and clinically significant improvement in median disease-free survival with RENCAREX® Munich, Germany, 26 February 2013 –... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - February 26, 2013 Category: Pharmaceuticals Source Type: clinical trials

Follow-up Data Show ZYTIGA Plus Prednisone Continues to Delay Progression of Metastatic Castration-Resistant Prostate Cancer in Patients without Prior Chemotherapy
ORLANDO, Fla., Feb. 12, 2013 /PRNewswire/ -- Janssen Research & Development, LLC [Janssen] announced today updated results showing ZYTIGA® (abiraterone acetate) plus prednisone continued to provide statistically significant... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - February 13, 2013 Category: Pharmaceuticals Source Type: clinical trials

Rockwell Medical Announces Iron Delivery Drug SFP Meets Primary Endpoint in PRIME Clinical Study Demonstrating Statistically Significant 37% Reduction in ESA Dose
- Unique iron drug maintains hemoglobin while greatly decreasing need for ESA - WIXOM, Mich., Feb. 4, 2013 /PRNewswire/ -- Rockwell Medical (NASDAQ: RMTI), a fully-integrated biopharmaceutical company targeting end-stage renal disease (ESRD)... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - February 5, 2013 Category: Pharmaceuticals Source Type: clinical trials

Amarantus BioScience Reports Statistical Significance Achieved for MANF Striatal Reinnervation in Neurorestoration Animal Model of Parkinson's Disease
SUNNYVALE, Calif., Feb. 4, 2013 /PRNewswire/ -- Amarantus BioScience, Inc. (OTCQB: AMBS), a biotechnology company discovering and developing treatments and diagnostics for diseases associated with neurodegeneration and apoptosis... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - February 4, 2013 Category: Pharmaceuticals Source Type: clinical trials

Data from Historic Phase IIb Clinical Trial for Tuberculosis Vaccine Candidate MVA85A Published in The Lancet
-Vaccine candidate was generally well tolerated, meeting the study’s primary objective of safety -Vaccine candidate did not provide statistically-significant protection in preventing TB disease in infants previously vaccinated with... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - February 4, 2013 Category: Pharmaceuticals Source Type: clinical trials

Data from Historic Phase IIb Clinical Trial for Tuberculosis Vaccine Candidate MVA85A Published in The Lancet
Vaccine candidate was generally well tolerated, meeting the study's primary objective of safety Vaccine candidate did not provide statistically-significant protection in preventing TB disease in infants previously vaccinated with... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - February 4, 2013 Category: Pharmaceuticals Source Type: clinical trials

ABRAXANE Plus Gemcitabine Improves Survival in Phase III Study of Patients with Advanced Pancreatic Cancer
ABRAXANE plus gemcitabine demonstrated highly statistically significant and clinically meaningful results across primary and key secondary endpoints and patient subgroups ABRAXANE plus gemcitabine patients showed 59% higher chance of survival at one... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - January 25, 2013 Category: Pharmaceuticals Source Type: clinical trials

ABRAXANE Plus Gemcitabine Demonstrates Significant Survival Advantage in Phase III Study of Patients with Advanced Pancreatic Cancer
Abraxane plus gemcitabine was superior to gemcitabine alone with statistically significant and clinically meaningful results across primary and key secondary endpoints and patient subgroups Oral Presentation Scheduled for Friday, January 25th at... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - January 25, 2013 Category: Pharmaceuticals Source Type: clinical trials

The Medicines Company Announces Positive Results in a Phase 3 Trial of Cangrelor in the Treatment of Patients Undergoing PCI
CHAMPION PHOENIX Trial Meets Protocol-Specified Predefined Efficacy Endpoint; Intravenous Bolus and Infusion of Cangrelor Provided Statistically Significant Improvement in Ischemic Events at 48 Hours in Patients Undergoing PCI Jan 08, 2013... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - January 9, 2013 Category: Pharmaceuticals Source Type: clinical trials

Apremilast Esteem Program Meets Primary and Major Secondary Endpoint in Pivotal Phase Iii Psoriasis Trials
Clinical Data from two pivotal phase III (ESTEEM 1&2) randomized, placebo-controlled studies including approximately 1,250 patients demonstrated statistically significant and clinically meaningful improvements for the primary and major secondary... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - January 7, 2013 Category: Pharmaceuticals Source Type: clinical trials

Idera Pharmaceuticals Announces Positive Top-line Results from Phase 2 Trial of IMO-3100 in Patients with Moderate-to-Severe Plaque Psoriasis
TLR antagonist achieves statistically significant improvement in PASI scores after four weeks of treatment Reduction in PASI score sustained for up to four weeks post-treatment CAMBRIDGE, Mass.--(BUSINESS WIRE)--Dec 19, 2012 - Idera Pharmaceuticals... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - December 19, 2012 Category: Pharmaceuticals Source Type: clinical trials

Phase II Data Presented at Acnp 2012 Shows Novel Antidepressant Glyx-13 Significantly Reduces Depression Scores Within Hours
—A Single Dose of Naurex’s Novel NMDA Receptor Modulator Produce Statistically Significant Reductions in Depression Scores Within 24 Hours that Lasted 7 Days in Subjects Who Had Failed Other Therapies— —Antidepressant... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - December 10, 2012 Category: Pharmaceuticals Source Type: clinical trials

Phase II Data Presented at ACNP 2012 Shows Novel Antidepressant GLYX-13 Significantly Reduces Depression Scores Within Hours
-- A Single Dose of Naurex's Novel NMDA Receptor Modulator Produced Statistically Significant Reductions in Depression Scores Within 24 Hours that Lasted 7 Days in Subjects Who Had Failed Other Therapies -- -- Antidepressant Efficacy as Measured by... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - December 6, 2012 Category: Pharmaceuticals Source Type: clinical trials

Chelsea Therapeutics Announces Northera (Droxidopa) Study 306B Meets Primary Endpoint
-- Northera(TM) Demonstrated Statistically Significant Improvement OverPlacebo in Reduction of Dizziness/Lightheadedness at Week 1 (p=0.018), the Primary Endpoint, and Standing Blood Pressure at Week 1 (p=0.032), a Key Secondary Endpoint -- Northera... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - December 5, 2012 Category: Pharmaceuticals Source Type: clinical trials

AcelRx Announces Primary Endpoint Met in Phase 3 Non-Inferiority Study of Sublingual Sufentanil NanoTab PCA System vs. IV PCA Morphine for Post-Operative Pain
-In this open-label study, the Sufentanil NanoTab PCA System also demonstrated statistical superiority to IV PCA morphine for primary endpoint of Patient Global Assessment of method of pain control REDWOOD CITY, Calif., Nov. 15, 2012 /PRNewswire/ --... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - November 16, 2012 Category: Pharmaceuticals Source Type: clinical trials

Oral Apremilast Achieves Statistical Significance for the Primary Endpoint of ACR20 in the First Phase III Study (PALACE-1) in Patients with Psoriatic Arthritis
Apremilast significantly improves signs and symptoms of PsA in DMARDs-failure patients, including biologic-treatment-failure patients Apremilast monotherapy demonstrates robust improvement across primary and secondary endpoints Highest response... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - November 13, 2012 Category: Pharmaceuticals Source Type: clinical trials

Abbott Announces First Long-term Patient-reported Health Outcomes Data for Investigational Use of HUMIRA(R) (Adalimumab) in Patients with Active Non-Radiographic Axial Spondyloarthritis (nr-axSpA)
-In the Phase 3 ABILITY-1 trial, HUMIRA patients experienced a statistically significant improvement in select measures of physical function and health-related quality of life (HRQOL) at 12 weeks -Post-hoc analysis of data showed that nr-axSpA... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - November 12, 2012 Category: Pharmaceuticals Source Type: clinical trials

Santarus and Pharming Announce Positive Top-Line Phase III Results for Ruconest in Acute Hereditary Angioedema
Statistically significant results for primary endpoint of time to beginning of symptom relief SAN DIEGO & LEIDEN, Netherlands--(BUSINESS WIRE)--Nov 7, 2012 - Santarus, Inc. (NASDAQ: SNTS) and Pharming Group NV (NYSE Euronext: PHARM) today... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - November 7, 2012 Category: Pharmaceuticals Source Type: clinical trials

Bayer's Investigational Riociguat Meets Primary Endpoint in Phase III Study in Patients with Pulmonary Arterial Hypertension (PAH)
• Riociguat demonstrates a statistically significant improvement in the six-minute walk test (6MWT) in both treatment-naïve patients and in patients pre-treated with endothelin receptor antagonists (ERAs) or non-intravenous... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - October 22, 2012 Category: Pharmaceuticals Source Type: clinical trials

Pfizer Announces Top-line Results From Phase 3 Trial Of INLYTA (axitinib) In Treatment-Naïve Patients With Advanced Renal Cell Carcinoma
NEW YORK--(BUSINESS WIRE)--Oct 17, 2012 - Pfizer Inc. announced today that a Phase 3 study of INLYTA® (axitinib) did not meet its primary endpoint of demonstrating statistically significantly longer progression-free survival (PFS),... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - October 17, 2012 Category: Pharmaceuticals Source Type: clinical trials

EXPAREL as the Foundation of a Multimodal Regimen Achieves Statistical Significance in All Primary Endpoints, Including a 60 Percent Reduction in Length of Hospital Stay
IMPROVE trial compares the cost of care between a standard opioid-based regimen and an EXPAREL-based multimodal regimen for postsurgical pain management PARSIPPANY, N.J.--(BUSINESS WIRE)--Oct 8, 2012 - Pacira Pharmaceuticals, Inc. (NASDAQ:... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - October 8, 2012 Category: Pharmaceuticals Source Type: clinical trials

Santarus Announces Publication of Results from UCERIS Pivotal Study in Gastroenterology
UCERIS 9 mg statistically more effective than placebo for inducing remission in patients with active, mild to moderate ulcerative colitis SAN DIEGO--(BUSINESS WIRE)--Sep 27, 2012 - Santarus, Inc. (NASDAQ: SNTS) today announced that results from its... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - September 27, 2012 Category: Pharmaceuticals Source Type: clinical trials

Interim Data From Peregrine's Phase II Trial in Second-Line Non-Small Cell Lung Cancer Demonstrate Doubling of Median Overall Survival in Bavitiximab-Containing Arms
TUSTIN, CA -- (Marketwire) -- 09/07/12 -- • Interim Data from Double-Blind, Placebo-Controlled Trial Presented at Late-Breaking Plenary Session at Leading Oncology Symposium • Data Show Statistically Significant Improvement in... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - September 14, 2012 Category: Pharmaceuticals Source Type: clinical trials

Interim Data From Peregrine's Phase II Trial in Second-Line Non-Small Cell Lung Cancer Demonstrate Doubling of Median Overall Survival in Bavituximab-Containing Arms
TUSTIN, CA -- (Marketwire) -- 09/07/12 -- •Interim Data from Double-Blind, Placebo-Controlled Trial Presented at Late-Breaking Plenary Session at Leading Oncology Symposium •Data Show Statistically Significant Improvement in... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - September 10, 2012 Category: Pharmaceuticals Source Type: clinical trials

Eklira Genuair Provides Meaningful and Sustained Bronchodilation From the First Dose
Patients prefer the Genuair® inhaler over HandiHaler® • Eklira® Genuair® (aclidinium bromide) showed a clinically meaningful and statistically significant improvement in bronchodilation vs placebo along a 6-week study, as well... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - September 5, 2012 Category: Pharmaceuticals Source Type: clinical trials

Sosei Group Corporation QVA149 Phase III Study Meets Primary Endpoint in Reducing Exacerbations in COPD Patients and Filings in EU and Japan by End of Year
TOKYO, August 30, 2012/PRNewswire-FirstCall/ -- - SPARK demonstrated QVA149 statistically significantly reduced rate of moderate-to-severe exacerbations compared to glycopyrronium... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - August 30, 2012 Category: Pharmaceuticals Source Type: clinical trials

Novartis QVA149 Phase III Study Meets Primary Endpoint in Reducing Exacerbations in COPD Patients, Filing in EU and Japan by End of Year
• SPARK demonstrated QVA149 statistically significantly reduced rate of moderate-to-severe exacerbations compared to glycopyrronium 50 mcg[1] • Study showed QVA149 statistically significantly reduced overall exacerbation rates compared to... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - August 30, 2012 Category: Pharmaceuticals Source Type: clinical trials

Senesco Announces Highly Statistically Significant Tumor Growth Inhibition by a Combination of Lenalidomide and SNS01-T in Cancer Model
No Tumor Regrowth 8 Weeks after End of Treatment BRIDGEWATER, N.J.--(BUSINESS WIRE)--Aug 13, 2012 - Senesco Technologies, Inc. (“Senesco” or the “Company”) (NYSE MKT: SNT) announced today the results from the completed... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - August 13, 2012 Category: Pharmaceuticals Source Type: clinical trials

Nymox Reports Positive Results From Combined Statistical Analysis of Long Term Follow-Up Studies of BPH Drug
HASBROUCK HEIGHTS, N.J., July 31, 2012 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (Nasdaq:NYMX) reported positive results from a new study of long-term treatment outcomes for men who had received a single injection of NX-1207 2.5 mg for... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - August 2, 2012 Category: Pharmaceuticals Source Type: clinical trials

Spectrum Pharmaceuticals Announces Outstanding ZEVALIN Clinical Data In Aggressive Relapsed/Refratory Lymphoma; Presented at the 17th Congress of the European Hematology Association
Impressive and statistically significant (p=0.03) overall survival rate of 91% with ZEVALIN plus high dose chemotherapy (Z-BEAM) vs. 62% with BEAM chemotherapy alone was seen in aggressive relapsed/refractory lymphoma. Early data published in... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - June 18, 2012 Category: Pharmaceuticals Source Type: clinical trials

Updated Analysis of Phase III ALSYMPCA Study for Bayer's Investigational Compound Radium-223 Dichloride to be Presented at the 48th Annual ASCO Meeting
Radium-223 dichloride significantly increased overall survival and led to a statistically significant delay in time to first skeletal-related event in patients with castration-resistant prostate cancer with bone metastases LBA #4512 WAYNE,... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - June 4, 2012 Category: Pharmaceuticals Source Type: clinical trials

Auxilium Pharmaceuticals, Inc. Announces Positive Top-line Results from Both Phase III Trials of XIAFLEX for the Potential Treatment of Peyronie's Disease
XIAFLEX Demonstrated Statistically Significant Improvement in the Co-Primary Endpoints of Penile Curvature Deformity and Patient-Reported Bother versus Placebo Auxilium to Host Conference Call and Webcast on Monday, June 4 at 8:00 a.m.... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - June 4, 2012 Category: Pharmaceuticals Source Type: clinical trials

BioSpecifics Technologies Corp. Announces Positive Top-Line Phase III Data from XIAFLEX Clinical Trials for Treatment of Peyronie's Disease
- XIAFLEX Demonstrated Statistically Significant Improvements in Two Co-Primary Endpoints - - Supplemental Biologics License Application (sBLA) Filing Expected by End of 2012 - LYNBROOK, N.Y., June 4, 2012 /PRNewswire/ -- BioSpecifics Technologies... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - June 4, 2012 Category: Pharmaceuticals Source Type: clinical trials

Lundbeck's Lu AE58054 Meets Primary Endpoint in Large Placebo-Controlled Clinical Proof of Concept Study in People With Alzheimer's Disease
•Patients receiving the investigational compound Lu AE58054 achieved statistically significant improvement in cognitive performance when added to donepezil •In the clinical study Lu AE58054 was well-tolerated in combination with... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - May 29, 2012 Category: Pharmaceuticals Source Type: clinical trials

SLA Pharma AG Announces Clinically and Statistically Significant Phase 2 Results on Opioid Induced Constipation
BASEL, Switzerland & LONDON--(BUSINESS WIRE)--May 14, 2012 - S.L.A. Pharma AG has announced clinically and statistically significant top-line data from their Phase 2 double blind randomised placebo controlled study. The study was designed... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - May 14, 2012 Category: Pharmaceuticals Source Type: clinical trials

Statistically Significant Clinical Phase III Results of Lu AA21004 Provide Basis for Submission of An NDA and MAA for Major Depression (MDD)
•New clinical phase III data demonstrate the efficacy of the investigational compound Lu AA21004 compared to placebo in the treatment of MDD seen in several previous studies •Data from six out of eight short-term placebo... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - May 14, 2012 Category: Pharmaceuticals Source Type: clinical trials

KYTHERA Biopharmaceuticals Announces Presentation of Positive Results from First of Two ATX-101 European Phase III Trials for Reduction of Submental Fat
Results from Study 16 demonstrate statistically significant reduction in submental (under the chin) fat on clinician, patient and objective ratings LOS ANGELES--(BUSINESS WIRE)--May 7, 2012 - KYTHERA Biopharmaceuticals, Inc.... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - May 7, 2012 Category: Pharmaceuticals Source Type: clinical trials

AVEO Announces Preliminary Results of Exploratory Phase 2 Study Evaluating HGF Inhibitor in First-Line Patients with Advanced Lung Cancer
Ficlatuzumab/Gefitinib Combination Was Well-Tolerated and Demonstrated Clinical Activity; Study Results Did Not Reach Statistical Significance Encouraging Signals of Anti-tumor Activity in Distinct Subpopulations CAMBRIDGE, Mass.--(BUSINESS... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - May 2, 2012 Category: Pharmaceuticals Source Type: clinical trials

Ampio Pharmaceuticals announces extended analysis of Ampion In the Knee (AIK) Study shows pain relief of osteoarthritis, 84 days after a single injection into the knee, is statistically significant
GREENWOOD VILLAGE, Colo., April 30, 2012 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (Nasdaq: AMPE), a biopharmaceutical company conducting clinical trials on its three lead drugs (Ampion™, Optina™ and Zertane™), licensing... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - April 30, 2012 Category: Pharmaceuticals Source Type: clinical trials

Abbott's Investigational Treatment for Advanced Parkinson's Disease Demonstrates Positive Results in Phase 3 Clinical Trial
Statistically Significant Improvements in 'Off' Time Over Standard Oral Treatment; Data to Be Presented at American Academy of Neurology Annual Meeting Date: April 17, 2012 Abbott Park, Illinois (NYSE: ABT) — Abbott announced today the results... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - April 18, 2012 Category: Pharmaceuticals Source Type: clinical trials

Allergan Announces Positive Top-Line Results from Phase III Botox Overactive Bladder Program
-- Phase III Studies Show Statistically Significant Decrease in Urinary Incontinence Episodes -- IRVINE, Calif.--(BUSINESS WIRE)--Mar 28, 2012 - Allergan, Inc. (NYSE: AGN) today announced that two Phase III clinical trials of BOTOX®... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - March 28, 2012 Category: Pharmaceuticals Source Type: clinical trials

Roche's Roactemra Monotherapy Showed Superior Improvement in Rheumatoid Arthritis Signs and Symptoms Versus Adalimumab Monotherapy
Basel, 2 March 2012 - Statistically significant greater improvement in signs and symptoms, as measured by mean change in DAS28 (primary endpoint), DAS28 remission and low disease activity, ACR20, 50 and 70 (secondary endpoints) Roche (SIX: RO, ROG;... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - March 2, 2012 Category: Pharmaceuticals Source Type: clinical trials

Genentech's Actemra Monotherapy Showed Superior Improvement in Rheumatoid Arthritis Signs and Symptoms Versus Adalimumab Monotherapy
-- Statistically Significant Greater Improvement in Signs and Symptoms, As Measured by Mean Change in DAS28 (Primary Endpoint), DAS28 Remission and Low Disease Activity, ACR20, 50 and 70 (Secondary Endpoints) -- SOUTH SAN FRANCISCO,... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - March 2, 2012 Category: Pharmaceuticals Source Type: clinical trials

AltheRx Presents Positive Phase II Results of Solabegron in Overactive Bladder at the European Association of Urology Congress
Solabegron produced statistically significant improvements in symptoms of overactive bladder (OAB) compared to placebo and was safe and well-tolerated Solabegron, a novel beta3-adrenoceptor agonist with high affinity and selectivity, is also... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - March 1, 2012 Category: Pharmaceuticals Source Type: clinical trials

Argos Therapeutic Arcelis Immunotherapy AGS-003 in Combination With Sunitinib Shows Statistically Significant Correlation of Immune System Response to Overall Survival in Phase 2 Study in Patients with Advanced Renal Cell Carcinoma (RCC)
-High Resolution Immune Monitoring Analysis Shows AGS-003 in Combination With Sunitinib Overcomes Immuno-Suppressive Environment of RCC and Induces Tumor-Specific Multi-Functional Memory Cytotoxic T Lymphocytes (CTL) in Phase 2 Study- DURHAM,... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - January 31, 2012 Category: Pharmaceuticals Source Type: clinical trials